CN110959007A - 作为acc抑制剂的化合物及其应用 - Google Patents

作为acc抑制剂的化合物及其应用 Download PDF

Info

Publication number
CN110959007A
CN110959007A CN201880048775.2A CN201880048775A CN110959007A CN 110959007 A CN110959007 A CN 110959007A CN 201880048775 A CN201880048775 A CN 201880048775A CN 110959007 A CN110959007 A CN 110959007A
Authority
CN
China
Prior art keywords
alkyl
membered
radical
heteroatoms
alkylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880048775.2A
Other languages
English (en)
Other versions
CN110959007B (zh
Inventor
王勇
赵立文
王亚洲
全旭
姜春环
陈宏雁
陈孟华
李超
廖业欣
刘奇
王琛
王海
杨圣伟
郑国闯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Sanhome Pharmaceutical Co Ltd
Original Assignee
Nanjing Sanhome Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Sanhome Pharmaceutical Co Ltd filed Critical Nanjing Sanhome Pharmaceutical Co Ltd
Publication of CN110959007A publication Critical patent/CN110959007A/zh
Application granted granted Critical
Publication of CN110959007B publication Critical patent/CN110959007B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

一类作为乙酰辅酶A羧化酶(ACC)抑制剂的化合物及其应用，具体地，提供式I所示的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药，它们的制备方法以及含有这些化合物的药物组合物和这些化合物或组合物用于治疗和/或预防ACC表达相关疾病，例如纤维化疾病、代谢性疾病、癌症或者组织增生类疾病的用途。该化合物对ACC具有良好的抑制活性，非常有望成为纤维化疾病、代谢性疾病、癌症或者组织增生类疾病的治疗药物。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880048775.2A 2017-07-26 2018-07-25 作为acc抑制剂的化合物及其应用 Active CN110959007B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710616033 2017-07-26
CN2017106160332 2017-07-26
PCT/CN2018/096930 WO2019020041A1 (zh) 2017-07-26 2018-07-25 作为acc抑制剂的化合物及其应用

Publications (2)

Publication Number Publication Date
CN110959007A true CN110959007A (zh) 2020-04-03
CN110959007B CN110959007B (zh) 2022-07-01

Family

ID=65040002

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810829055.1A Active CN109305976B (zh) 2017-07-26 2018-07-25 作为acc抑制剂的化合物及其应用
CN201880048775.2A Active CN110959007B (zh) 2017-07-26 2018-07-25 作为acc抑制剂的化合物及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810829055.1A Active CN109305976B (zh) 2017-07-26 2018-07-25 作为acc抑制剂的化合物及其应用

Country Status (8)

Country Link
US (1) US11186587B2 (zh)
EP (1) EP3660023B1 (zh)
JP (1) JP6919055B2 (zh)
KR (1) KR102418195B1 (zh)
CN (2) CN109305976B (zh)
CA (1) CA3070525C (zh)
TW (1) TW201910338A (zh)
WO (1) WO2019020041A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111484504A (zh) * 2019-01-25 2020-08-04 南京圣和药业股份有限公司 Acc抑制剂的光学异构体及其应用
CN113968871A (zh) * 2020-07-25 2022-01-25 南京圣和药业股份有限公司 苯基取代类acc抑制剂的晶型

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10995099B2 (en) * 2017-07-17 2021-05-04 Nanjing Ruijie Pharmatech Co., Ltd. Compounds and their uses as ACC inhibitors
CN111848678A (zh) * 2019-04-30 2020-10-30 正大天晴药业集团股份有限公司 含磷类噻吩并嘧啶衍生物
CN112778325A (zh) * 2019-11-07 2021-05-11 南京瑞捷医药科技有限公司 一种acc抑制剂及其用途
WO2021112213A1 (ja) * 2019-12-05 2021-06-10 日本曹達株式会社 ２，４－ジオキソ－１，４－ジヒドロチエノピリミジン化合物、及びそれを含有する農園芸用殺菌剤又は医療用・動物用抗真菌剤
CN113967213A (zh) * 2020-07-25 2022-01-25 南京圣和药业股份有限公司 一种包含苯基取代类acc抑制剂的组合物及其用途
CN116745299A (zh) * 2021-02-07 2023-09-12 正大天晴药业集团股份有限公司 噻吩并嘧啶衍生物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104105485A (zh) * 2011-11-11 2014-10-15 尼普斯阿波罗有限公司 Acc抑制剂和其用途
WO2017075056A1 (en) * 2015-10-26 2017-05-04 Gilead Apollo, Llc Acc inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103776A2 (en) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
WO2015007451A1 (en) * 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2016112305A1 (en) * 2015-01-09 2016-07-14 Nimbus Apollo, Inc. Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
EP3571205B1 (en) * 2017-01-22 2023-08-30 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
CN110709402B (zh) * 2017-06-15 2022-05-10 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途
US10995099B2 (en) * 2017-07-17 2021-05-04 Nanjing Ruijie Pharmatech Co., Ltd. Compounds and their uses as ACC inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104105485A (zh) * 2011-11-11 2014-10-15 尼普斯阿波罗有限公司 Acc抑制剂和其用途
WO2017075056A1 (en) * 2015-10-26 2017-05-04 Gilead Apollo, Llc Acc inhibitors and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111484504A (zh) * 2019-01-25 2020-08-04 南京圣和药业股份有限公司 Acc抑制剂的光学异构体及其应用
CN111484504B (zh) * 2019-01-25 2024-05-10 南京圣和药业股份有限公司 Acc抑制剂的光学异构体及其应用
CN113968871A (zh) * 2020-07-25 2022-01-25 南京圣和药业股份有限公司 苯基取代类acc抑制剂的晶型

Also Published As

Publication number Publication date
CN109305976B (zh) 2022-07-01
KR20200032158A (ko) 2020-03-25
JP2020527160A (ja) 2020-09-03
JP6919055B2 (ja) 2021-08-11
EP3660023A4 (en) 2021-05-26
EP3660023B1 (en) 2023-03-08
EP3660023A1 (en) 2020-06-03
WO2019020041A1 (zh) 2019-01-31
CN109305976A (zh) 2019-02-05
US20200165265A1 (en) 2020-05-28
CA3070525C (en) 2022-03-15
TW201910338A (zh) 2019-03-16
CA3070525A1 (en) 2019-01-31
KR102418195B1 (ko) 2022-07-07
US11186587B2 (en) 2021-11-30
CN110959007B (zh) 2022-07-01

Similar Documents

Publication Publication Date Title
CN109305976B (zh) 作为acc抑制剂的化合物及其应用
JP7017521B2 (ja) アクチビン受容体様キナーゼの阻害剤
US10000507B2 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US20240034729A9 (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
WO2020239077A1 (zh) 含氮杂环类衍生物调节剂、其制备方法和应用
CN111433200A (zh) 用于治疗疾病的新化合物及其药物组合物
ES2784477T3 (es) Acidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
TWI683811B (zh) 二氫噠嗪-３,５-二酮衍生物
CN111499634A (zh) 一种喹唑啉化合物及其在医药上的应用
CN105524068A (zh) 氮杂双环衍生物、其制法与医药上的用途
JP2021527106A (ja) 新規化合物及び疾患の治療のためのその医薬組成物
CN111484504B (zh) Acc抑制剂的光学异构体及其应用
TWI723480B (zh) 用作fgfr4抑制劑的稠環衍生物
CN107072993B (zh) 含有钠依赖性磷酸转运蛋白抑制剂的药物
JP7301222B2 (ja) Ｐｒｍｔ５阻害剤としての置換三環類化合物及びその応用
WO2016030852A1 (en) P38 map kinase inhibiting indanyl urea compounds
CN113968872A (zh) 苯基取代类acc抑制剂的制备方法
CN116262749A (zh) 一类芳杂环取代的化合物及其制备方法和用途
WO2024061333A1 (zh) 一种kras突变蛋白抑制剂、及其制备方法和应用
WO2024093956A1 (zh) 多环类聚(adp核糖)聚合酶选择性抑制剂
WO2023237085A1 (zh) Hpk1抑制剂及其在医药上的应用
CN117813293A (zh) 可用于治疗癌症的脲衍生物
CN113968871A (zh) 苯基取代类acc抑制剂的晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40019680

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant